A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
Public ClinicalTrials.gov record NCT05766501. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Open-label Clinical Study of Doravirine/Islatravir (DOR/ISL [100 mg/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL (100 mg/0.75 mg) QD in a Phase 3 Clinical Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with DOR/ISL in earlier clinical studies. There are no formal hypotheses to be tested in this study.
Study identification
- NCT ID
- NCT05766501
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 641 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 16, 2023
- Primary completion
- Oct 15, 2025
- Completion
- Sep 5, 2028
- Last update posted
- Dec 16, 2025
2023 – 2028
United States locations
- U.S. sites
- 31
- U.S. states
- 12
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham-UAB 1917 Research Clinic ( Site 3104) | Birmingham | Alabama | 35222 | — |
| Pueblo Family Physicians ( Site 3102) | Phoenix | Arizona | 85015 | — |
| Pacific Oaks Medical Group ( Site 3123) | Beverly Hills | California | 90211 | — |
| Kaiser Permanente ( Site 3124) | Los Angeles | California | 90027 | — |
| Ruane Clinical Research Group, Inc ( Site 3126) | Los Angeles | California | 90036 | — |
| Mills Clinical Research ( Site 3114) | Los Angeles | California | 90069 | — |
| University of California Davis Health-Internal Medicine: Infectious Diseases ( Site 3137) | Sacramento | California | 95817 | — |
| Georgetown University Medical Center ( Site 3130) | Washington D.C. | District of Columbia | 20007 | — |
| Therafirst Medical Center ( Site 3110) | Fort Lauderdale | Florida | 33308 | — |
| Midway Immunology and Research Center ( Site 3117) | Ft. Pierce | Florida | 34982 | — |
| AHF The Kinder Medical Group ( Site 3108) | Miami | Florida | 33133 | — |
| Floridian Clinical Research, LLC ( Site 3133) | Miami Lakes | Florida | 33016 | — |
| Orlando Immunology Center ( Site 3106) | Orlando | Florida | 32803 | — |
| Bliss Healthcare Services ( Site 3115) | Orlando | Florida | 32806 | — |
| CAN Community Health - Sarasota ( Site 3118) | Sarasota | Florida | 34237 | — |
| Triple O Research Institute, P.A ( Site 3116) | West Palm Beach | Florida | 33407 | — |
| Augusta University-Infectious Diseases ( Site 3135) | Augusta | Georgia | 30912 | — |
| Infectious Disease Specialists of Atlanta ( Site 3128) | Decatur | Georgia | 30033 | — |
| Mercer university, Department of internal medicine-Clinical Research ( Site 3129) | Macon | Georgia | 31201 | — |
| Chatham County Health Department - Chatham CARE Center-Infectious Disease ( Site 3105) | Savannah | Georgia | 31401 | — |
| KC CARE Health Center ( Site 3103) | Kansas City | Missouri | 64111 | — |
| ID Care ( Site 3131) | Hillsborough | New Jersey | 08844 | — |
| Icahn School of Medicine at Mount Sinai-Clinical and Translational Research Center ( Site 3134) | New York | New York | 10029 | — |
| Penn Medicine: University of Pennsylvania Health System-Perelman Center for Advanced Medicine ( Site | Philadelphia | Pennsylvania | 19104 | — |
| St Hope Foundation ( Site 3121) | Bellaire | Texas | 77401 | — |
| North Texas Infectious Diseases Consultants, P.A ( Site 3100) | Dallas | Texas | 75246 | — |
| Texas Centers for Infectious Disease Associates ( Site 3111) | Fort Worth | Texas | 76104 | — |
| The Crofoot Research Center ( Site 3101) | Houston | Texas | 77098 | — |
| DCOL Center for Clinical Research ( Site 3119) | Longview | Texas | 75605 | — |
| Private Practice - Dr. Peter Shalit ( Site 3120) | Seattle | Washington | 98104 | — |
| Multicare Institute for Research and Innovation ( Site 3127) | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05766501, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 16, 2025 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05766501 live on ClinicalTrials.gov.